Anders Rylander intervjuad i Analysguiden
Anders Rylander, VD Biovica intervjuas i Aktiespararnas Analysguiden. I intervjun diskuteras den planerade noteringen av Biovica på Nasdaq First North i mars 2017.
Biovica presenterar på Unicorn Summit kapitalmarknadsdagar 2017
Anders Rylander, VD kommer att presentera Biovica på Unicorn Summit i Stockholm den 7 mars 2017. Presentationen genomförs som en del av bolagets investerarpresentationer i samband med den planerade börsintroduktion på Nadaq First North i mars 2017. Syftet med noteringen är att vidareutveckla bolag och initiera kommersialiseringen av bolagets test, DiviTum ™ - ett [...]
Biovica presents at Unicorn Summit 2017
Anders Rylander, CEO will present at the Vator Securities Unicorn Summit in Stockholm on March 7, 2017. The presentation, part of the company’s planned IPO on Nasdaq First North in March 2017, is intended for investors. The purpose of the IPO is to raise funds to initiate the commercialization phase of the company’s DiviTum™ [...]
Biovica strengthens its management
Uppsala, Sweden, February 20, 2017. Biovica has strengthened its management team to ensure continued successful development. Cecilia Driving (CFO), Karin Mattsson (R&D Director) and Johanna Faris (Quality and Regulatory Assurance Director) have joined the company.
Nya resultat för DiviTum™ som effektmarkör för CDK4/6 hämmare presenteras på AACR
Uppsala, Sverige, 16 februari, 2017. Den årliga konferensen för American Association for Cancer Research (AACR) den 1-5 april är en av de största vetenskapliga konferenserna för cancerforskare och onkologer. Tillsammans med Dana Farber Cancer Institute och Karolinska Institutet kommer Biovica att presentera nya data på DiviTum™-teknologin som effektmarkör för CDK4/6-hämmare. "På AACR kommer vi [...]
New data on DiviTum will be presented at AACR
Uppsala, Sweden, February 16, 2017. The American Association for Cancer Research (AACR) Annual Meeting on April 1-5 will gather the world’s leading cancer researchers and oncologists. Together with its research partners Dana Farber Cancer Institute and the Karolinska Institute, Biovica will present new data on the company’s DiviTum™ assay as a response marker for CDK4/6 [...]
Biovica interviewed about the upcoming IPO
Anders Rylander, CEO of Biovica and Mattias Bergqvist, VP Marketing & Clinical Development discuss the challenges in cancer diagnostics, go-to-market strategies, clinical results and IPO preparations in the latest edition of Vatorpodden. The interview is available in Swedish (only)
Biovica discuss the latest clinical results in Vatorpodden
Listen to Anders Rylander, CEO of Biovica and Mattias Bergqvist VP Sales & Marketing being interviewed in the latest edition of Vatorpodden. Anders and Mattias discuss the latest clinical results presented at the 2016 San Antonio Breast Cancer Symposium. The interview is available in Swedish (only)
Biovica participates at SABCS, december 6-10, San Antonio
Biovica will attend the San Antonio Breast Cancer Symposium, an event that brings together oncology professionals from around the world. SABCS is the world’s leading breast cancer congress attracting more than 7,500 attendees from 90 countries. Read more at sabcs.org “At SABCS we will present new clinical study results in collaboration [...]
Meet Biovica at the World CDx Summit in Boston
Biovica will attend the 7th World Companion Diagnostic in Boston, October 18-21. The focus of the meeting is aligned with Biovicas strategy to rapidly progress exploratory biomarkers to registration, align clinical co-development and ensure reimbursement and market access success for precision therapies and assays. “At the World CDx meeting we look forward to meet partners [...]
Follow Biovica